The European LeukemiaNet is an EU-funded organisation of physicians, scientists and patients with interest in leukemia.
It aims to improve the treatment and knowledge about Leukemia in Europe and spread excellence. The website delivers
information for physicians, patients (e.g. patient organisations in Europe), ongoing clinical trials and
further information about the disease. You can get information about the European LeukemiaNet in
various european languages. The European LeukemiaNet is
funded by the 6th Framework Program of the European Community.
The most visible results of the ELN are the guidelines and management recommendations for virtually every leukemia and interdisciplinary speciality which have lain the groundwork for uniform definitions and standards required for common clinical trials and projects.
In July 2012, the European Commission prepared a proposal for the European Parliament, which is not a directive but a regulation. Couching the legislation as a regulation rather than a directive will ensure that the new rules, once finalized and adopted, will have an immediate and binding impact across the EU, avoiding ...
The 9th Information Letter is available online. For the first time, this issue contains summaries of the most important clinical results from oral presentations of the 54th ASH Annual Meeting which were selected and summarized by ELN experts.
In May 2012 the European Medicines Agency launched the new website www.adrreports.eu publishing suspected side-effect reports of drugs authorised in the European Economic Area. The website for the general public is available in all official European languages.
189 Participating Centers in 38 Countries (1000 Researchers and Associates) are cooperating in the European Leukemia Net. The objective is to integrate the 108 leading leukemia trial groups (CML, AML, ALL, CLL, MDS, CMPD), their 105 interdisciplinary partners (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a cooperative network for advancements in leukemia related research and health care (data updated March 2012).